FDA approves Camzyos for pediatric obstructive hypertrophic cardiomyopathy
Bristol Myers Squibb received FDA approval on September 30, 2026 to extend its cardiac myosin inhibitor Camzyos (mavacamten) to children aged 12 to 18 who weigh at least 30 kg (66 lb). The drug now treats symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients, addressing a previously unmet medical need. The approval was based on the Phase III Scout‑HCM trial, which showed a significant reduction in left ventricular outflow tract gradient. The company highlighted the milestone for young patients and families affected by this rare genetic heart condition.
Why it matters
The company says the expanded indication broadens Camzyos' market and provides the only FDA‑approved therapy for pediatric patients with this disease, potentially increasing sales (the company claims).
Key facts
- 1The FDA approved Camzyos for pediatric use on September 30, 2026. gurufocus.com
- 2The indication covers children aged 12 to 18 who weigh at least 30 kg (66 lb). pharmexec.com
- 3Camzyos treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and pediatric patients. morningstar.com
- 4The Phase III Scout‑HCM trial enrolled 44 adolescent patients and showed a mean Valsalva LVOT gradient change of -49.4 mmHg versus -1.8 mmHg for placebo. pharmexec.com
- 5No patients in the trial experienced left ventricular ejection fraction below 50%. pharmexec.com
- 6Bristol Myers Squibb's stock was trading at $62.84 at the time of the announcement. marketscreener.com
Open questions
- Dividend yield is reported as 3.88% in material 1 and 3.93% in material 5.
Summary written by AlphAI from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.